| Literature DB >> 33277927 |
Jimin Xu1, Yu Xue1, Richard Zhou1, Pei-Yong Shi2, Hongmin Li3,4, Jia Zhou1.
Abstract
In the past two decades, three highly pathogenic human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus, and, recently, SARS-CoV-2, have caused pandemics of severe acute respiratory diseases with alarming morbidity and mortality. Due to the lack of specific anti-CoV therapies, the ongoing pandemic of coronavirus disease 2019 (COVID-19) poses a great challenge to clinical management and highlights an urgent need for effective interventions. Drug repurposing is a rapid and feasible strategy to identify effective drugs for combating this deadly infection. In this review, we summarize the therapeutic CoV targets, focus on the existing small molecule drugs that have the potential to be repurposed for existing and emerging CoV infections of the future, and discuss the clinical progress of developing small molecule drugs for COVID-19.Entities:
Keywords: COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; anti-CoV; coronavirus; drug repurposing; drug targets; small molecule drugs
Mesh:
Substances:
Year: 2020 PMID: 33277927 PMCID: PMC8044022 DOI: 10.1002/med.21763
Source DB: PubMed Journal: Med Res Rev ISSN: 0198-6325 Impact factor: 12.944